
|Articles|June 1, 2014
Results from the Phase III CALGB/SWOG 80405 Trial
Author(s)Richard Goldberg, MD
Richard Goldberg, MD, discusses results from the phase III CALGB/SWOG 80405 trial at the 2014 ASCO Annual Meeting.
Advertisement
Richard Goldberg, MD, Physician-in-Chief at Ohio State’s Comprehensive Cancer Center James Cancer Hospital and Solove Research Institute, discusses results from the phase III CALGB/SWOG 80405 trial at the 2014 ASCO Annual Meeting. The CALGB/SWOG 80405 trial looked at irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab or cetuximab for patients with KRAS wild-type untreated metastatic adenocarcinoma of the colon or rectum (mCRC).
<<<
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















